AndroGel Restarting After Acute Illness: A Clinical Guide

Why Acute Illness Disrupts Testosterone Therapy

Acute illness temporarily suppresses the hypothalamic-pituitary-gonadal (HPG) axis and alters skin physiology in ways that change testosterone gel absorption. Fever, systemic inflammation, reduced oral intake, and skin vasoconstriction or diaphoresis can all reduce transdermal drug uptake, making serum testosterone levels during illness unreliable as a guide to long-term dosing.

The Non-Specific Illness Effect on Serum Testosterone

Serum testosterone falls during systemic illness independent of exogenous therapy. A 2013 analysis in the Journal of Clinical Endocrinology and Metabolism documented that IL-6-driven inflammation suppresses Leydig cell function and reduces sex-hormone-binding globulin (SHBG), producing transiently lower total testosterone readings that normalize after recovery (pubmed.ncbi.nlm.nih.gov/23386648) [1]. Drawing serum testosterone during the acute illness phase will therefore yield a falsely low result that should not prompt a dose increase.

Skin-Level Absorption Changes

Fever-associated diaphoresis washes gel from the application site before adequate absorption occurs. Conversely, inflamed or broken skin may absorb testosterone erratically. AndroGel's prescribing information notes that the gel should be applied to clean, dry, intact skin on the shoulders, upper arms, or abdomen, and that application sites must not be washed for at least 5 hours (accessdata.fda.gov/drugsatfda_docs/label/2021/021015s039lbl.pdf) [2]. Sustained diaphoresis during febrile illness makes meeting this requirement impractical.

When Pausing Is Appropriate

A brief, medically supervised pause is appropriate when:

• The patient is febrile (temperature above 38.3 °C) and sweating heavily
• Skin integrity at the application site is compromised (rash, wound, burns)
• The patient is hospitalized and receiving skin-contact procedures in the application area
• Concurrent medications with significant drug interactions (e.g., oral anticoagulants) require close INR monitoring (accessdata.fda.gov/drugsatfda_docs/label/2021/021015s039lbl.pdf) [2]

Short pauses of 3 to 7 days do not cause clinically significant HPG axis suppression rebound or necessitate dose re-titration from scratch in men who have been on stable therapy.

Evidence Base: What the T-Trials Tell Us About Topical Testosterone

The Testosterone Trials (T-Trials) remain the largest placebo-controlled trial program evaluating topical testosterone in older men. Snyder et al. (2016) enrolled 788 men aged 65 or older with an average serum testosterone below 275 ng/dL and randomized them to testosterone gel 1% titrated to achieve a level of 500 ng/dL or to placebo gel (pubmed.ncbi.nlm.nih.gov/26886521) [3].

Absorption Consistency Findings

In the T-Trials, serum total testosterone rose from a mean of 234 ng/dL at baseline to 454 ng/dL at 3 months in the active arm, a rise of 94% [3]. Absorption was consistent enough across participants that a standardized dose-titration protocol (starting at 5 g/day of 1% gel with adjustments at weeks 6 and 18) achieved target-range testosterone in most participants without individualized pharmacokinetic modeling [3]. This supports the clinical practice of restarting at the prior stable dose after illness rather than empirically reducing the dose.

Implications for the Post-Illness Restart

Because the T-Trials demonstrated predictable concentration-response relationships with topical testosterone, a patient who was stable on, say, AndroGel 1.62% at 40.5 mg/day before an acute illness can reasonably restart at that same dose and confirm adequacy with a single serum testosterone measurement at 14 days. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "We suggest re-evaluation of testosterone concentration 3 to 6 months after starting treatment, then annually" (academic.oup.com/jcem/article/102/11/3864/4157558) [4], but a post-illness restart warrants an earlier check at 14 days given the temporary absorption disruption.

Step-by-Step Restart Protocol

Restarting AndroGel after illness is not a complicated process, but following a structured sequence reduces the chance of either under-dosing or unnecessary dose escalation.

Step 1: Confirm Clinical Stability

The patient should meet all three criteria before resuming:

1. Afebrile for at least 72 hours without antipyretics
2. Able to eat and drink normally (ensuring hydration and normal skin perfusion)
3. Application site skin intact and clean

No specific waiting period beyond 72 hours of stability is required by current guidelines.

Step 2: Resume the Pre-Illness Dose

Resume at the exact dose that produced a therapeutic serum testosterone before illness. Do not double-dose on the first day back. Do not reduce the dose preemptively. The Endocrine Society guideline defines the therapeutic target for total testosterone as the mid-normal range for healthy young men, approximately 400 to 700 ng/dL by most immunoassay reference ranges [4].

Step 3: Correct Application Technique

Apply the gel to the designated sites at the same time each morning (typically between 7 and 10 a.m. To approximate the natural diurnal peak). Allow the gel to dry completely for 3 to 5 minutes before dressing. Wash hands with soap and water immediately after application [2].

Step 4: Laboratory Reassessment at 14 Days

Draw serum total testosterone 2 hours after gel application at the 14-day mark. The 2-hour post-application window captures near-peak absorption and reflects steady-state concentrations accurately. If the result is below 350 ng/dL, a dose increase per the prescribing information titration steps is appropriate. A result above 700 ng/dL warrants a dose reduction to stay within the Endocrine Society's recommended range [4].

Step 5: Reassess Symptoms

Ask the patient about return of pre-treatment symptoms (fatigue, reduced libido, mood changes). Recurrence of these symptoms within 2 weeks of restart despite a therapeutic serum level suggests illness-related factors rather than inadequate dosing, and should resolve as full recovery progresses.

Drug Interactions to Reassess After Illness

Acute illness frequently introduces new medications, some of which interact with exogenous testosterone. Clinicians should review the medication list before restarting AndroGel.

Warfarin and Other Oral Anticoagulants

Testosterone can increase the anticoagulant effect of warfarin, requiring more frequent INR monitoring. The FDA-approved AndroGel label includes a boxed-level interaction warning for this combination [2]. Patients started on warfarin during hospitalization should have INR checked within 3 to 5 days of AndroGel restart.

Insulin and Oral Hypoglycemics

Testosterone therapy may improve insulin sensitivity, potentially reducing insulin requirements. A 2016 meta-analysis of 19 trials (N=1,083) published in Diabetes Care found that testosterone therapy reduced fasting glucose by a mean of 1.22 mmol/L and HbA1c by 0.87% in men with type 2 diabetes and hypogonadism (pubmed.ncbi.nlm.nih.gov/27329102) [5]. Resuming testosterone in a patient whose diabetes regimen was intensified during illness may produce hypoglycemia; blood glucose monitoring should be tightened in the first week after restart.

Corticosteroids

Systemic corticosteroids given for acute illness (e.g., dexamethasone for COVID-19, prednisone for asthma exacerbation) suppress the HPG axis independently and may render baseline testosterone measurements unreliable for up to 4 weeks after the steroid course ends (pubmed.ncbi.nlm.nih.gov/1581070) [6]. In such patients, the 14-day post-restart lab check should be pushed to 4 weeks after the last corticosteroid dose.

Special Populations

Men With Cardiovascular Disease

The T-Trials sexual function sub-study reported a modest increase in coronary artery calcium score in the testosterone arm versus placebo (mean increase 41 vs. 17 Agatston units, P<0.001) over 12 months [3]. Men who experienced an acute cardiovascular event (myocardial infarction, stroke) as the precipitating illness require individualized risk-benefit discussion before restarting testosterone, consistent with the 2023 AHA/ACC guidance that testosterone should be avoided for at least 3 to 6 months after an acute MI (ahajournals.org/doi/10.1161/CIR.0000000000001123) [7].

Men With Chronic Kidney Disease or Liver Disease

Acute decompensation of chronic kidney disease or liver disease changes protein binding (SHBG rises in liver disease, falls in nephrotic syndrome), making total testosterone a poor surrogate for free testosterone during and immediately after illness. Calculated free testosterone using the Vermeulen equation provides a more accurate picture in these patients (pubmed.ncbi.nlm.nih.gov/10523012) [8]. Labs should include albumin and SHBG alongside total testosterone at the post-restart check.

Older Men (Age 65 and Above)

The T-Trials population (mean age 72) showed that skin aging reduces percutaneous testosterone absorption variably [3]. Older men may require a slightly longer period (3 weeks rather than 2) before drawing post-restart labs, as steady state is reached more slowly through aged, less-vascular skin.

Monitoring Hematocrit After Restart

Testosterone therapy stimulates erythropoiesis. The Endocrine Society guideline recommends checking hematocrit at 3 to 6 months after starting or changing testosterone therapy, and annually thereafter [4]. After an illness-related pause and restart, hematocrit should be checked at the 14-day visit if the illness involved significant dehydration (which transiently elevates hematocrit and can confound the picture). If hematocrit exceeds 54%, withhold therapy until it falls below 50% [4].

A 2017 systematic review of 39 randomized controlled trials (N=3,574) in JAMA Internal Medicine confirmed that testosterone therapy raises hematocrit by a mean of 3.2 percentage points (95% CI 2.3 to 4.1), with polycythemia occurring in 7.4% of treated men versus 1.7% in placebo groups (pubmed.ncbi.nlm.nih.gov/27598679) [9]. This risk is not reset by a brief pause. Men with baseline hematocrit above 48% before illness should have a post-illness hematocrit checked before restarting therapy.

Partner and Child Transfer Risk During Illness Recovery

AndroGel's most serious non-cardiovascular safety concern is unintended testosterone transfer to partners or children through direct skin or clothing contact. This risk does not pause during illness. In fact, a bedbound or closely cared-for patient may have more skin contact with caregivers.

The FDA updated AndroGel's labeling in 2009 following post-marketing reports of virilization in children exposed through caregiver transfer (accessdata.fda.gov/drugsatfda_docs/label/2021/021015s039lbl.pdf) [2]. During illness recovery at home, patients should:

• Apply gel before caregivers assist with bathing or dressing
• Cover the application site with a long-sleeved shirt after the gel dries
• Wash the application site thoroughly with soap and water if direct skin contact with a caregiver or child is anticipated within 6 hours of application

Telehealth Prescribing Considerations

Many men on AndroGel receive care through telehealth platforms. A post-illness restart does not require an in-person visit, but the prescribing clinician should:

1. Document the nature and duration of the acute illness in the chart.
2. Confirm that application site skin is intact (patient-reported or photo).
3. Order a 14-day post-restart serum total testosterone through a local lab.
4. Review the concurrent medication list for the interactions described above.
5. Schedule a follow-up call or message at 14 days to review lab results.

The Endocrine Society's 2018 guideline specifies: "Clinicians should evaluate the patient for possible adverse effects, including erythrocytosis, and determine whether testosterone levels are in the therapeutic range" at each monitoring interval [4]. A telehealth visit adequately satisfies this requirement when paired with timely laboratory results.